Literature DB >> 33680935

Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy.

Yue Li1,2, Jun Liu1, Hong-Xuan Li1, Xu-Wei Cai1, Zhi-Gang Li3, Xiao-Dan Ye4, Hao-Hua Teng5, Xiao-Long Fu1, Wen Yu1.   

Abstract

After neoadjuvant chemoradiotherapy (NCRT) in locally advanced esophageal squamous cell cancer (ESCC), roughly 40% of the patients may achieve pathologic complete response (pCR). Those patients may benefit from organ-saving strategy if the probability of pCR could be correctly identified before esophagectomy. A reliable approach to predict pathological response allows future studies to investigate individualized treatment plans.
METHOD: All eligible patients treated in our center from June 2012 to June 2019 were retrospectively collected. Radiomics features extracted from pre-/post-NCRT CT images were selected by univariate logistic and LASSO regression. A radiomics signature (RS) developed with selected features was combined with clinical variables to construct RS+clinical model with multivariate logistic regression, which was internally validated by bootstrapping. Performance and clinical usefulness of RS+clinical model were assessed by receiver operating characteristic (ROC) curves and decision curve analysis, respectively.
RESULTS: Among the 121 eligible patients, 51 achieved pCR (42.1%) after NCRT. Eighteen radiomics features were selected and incorporated into RS. The RS+clinical model has improved prediction performance for pCR compared with the clinical model (corrected area under the ROC curve, 0.84 vs. 0.70). At the 60% probability threshold cutoff (i.e., the patient would opt for observation if his probability of pCR was >60%), net 13% surgeries could be avoided by RS+clinical model, equivalent to implementing organ-saving strategy in 31.37% of the 51 true-pCR cases.
CONCLUSION: The model built with CT radiomics features and clinical variables shows the potential of predicting pCR after NCRT; it provides significant clinical benefit in identifying qualified patients to receive individualized organ-saving treatment plans.
Copyright © 2021 Li, Liu, Li, Cai, Li, Ye, Teng, Fu and Yu.

Entities:  

Keywords:  esophageal cancer; neoadjuvant chemoradiation; organ-saving treatment; radiomics; response prediction

Year:  2021        PMID: 33680935      PMCID: PMC7933499          DOI: 10.3389/fonc.2020.615167

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  38 in total

1.  L1 penalized estimation in the Cox proportional hazards model.

Authors:  Jelle J Goeman
Journal:  Biom J       Date:  2010-02       Impact factor: 2.207

2.  Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

Authors:  Bo Jan Noordman; Mathilde G E Verdam; Sjoerd M Lagarde; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast; Mirjam A G Sprangers; J Jan B van Lanschot
Journal:  J Clin Oncol       Date:  2017-11-21       Impact factor: 44.544

3.  Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Zhenyu Liu; Xiao-Yan Zhang; Yan-Jie Shi; Lin Wang; Hai-Tao Zhu; Zhenchao Tang; Shuo Wang; Xiao-Ting Li; Jie Tian; Ying-Shi Sun
Journal:  Clin Cancer Res       Date:  2017-09-22       Impact factor: 12.531

4.  Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.

Authors:  Florent Tixier; Catherine Cheze Le Rest; Mathieu Hatt; Nidal Albarghach; Olivier Pradier; Jean-Philippe Metges; Laurent Corcos; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

5.  Test-retest reproducibility analysis of lung CT image features.

Authors:  Yoganand Balagurunathan; Virendra Kumar; Yuhua Gu; Jongphil Kim; Hua Wang; Ying Liu; Dmitry B Goldgof; Lawrence O Hall; Rene Korn; Binsheng Zhao; Lawrence H Schwartz; Satrajit Basu; Steven Eschrich; Robert A Gatenby; Robert J Gillies
Journal:  J Digit Imaging       Date:  2014-12       Impact factor: 4.056

6.  Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PET-CT useful?

Authors:  Chee Way Eng; James Louis Fuqua; Ravinder Grewal; David Ilson; Antoine Cosme David Messiah; Nabil Rizk; Laura Tang; Marc J Gollub
Journal:  Clin Imaging       Date:  2012-09-13       Impact factor: 1.605

7.  Radiomic analysis in contrast-enhanced CT: predict treatment response to chemoradiotherapy in esophageal carcinoma.

Authors:  Zhen Hou; Wei Ren; Shuangshuang Li; Juan Liu; Yu Sun; Jing Yan; Suiren Wan
Journal:  Oncotarget       Date:  2017-11-06

8.  Japanese Classification of Esophageal Cancer, 11th Edition: part I.

Authors: 
Journal:  Esophagus       Date:  2016-11-10       Impact factor: 4.230

9.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.

Authors:  Hugo J W L Aerts; Emmanuel Rios Velazquez; Ralph T H Leijenaar; Chintan Parmar; Patrick Grossmann; Sara Carvalho; Sara Cavalho; Johan Bussink; René Monshouwer; Benjamin Haibe-Kains; Derek Rietveld; Frank Hoebers; Michelle M Rietbergen; C René Leemans; Andre Dekker; John Quackenbush; Robert J Gillies; Philippe Lambin
Journal:  Nat Commun       Date:  2014-06-03       Impact factor: 14.919

10.  Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.

Authors:  Hong Yang; Hui Liu; Yuping Chen; Chengchu Zhu; Wentao Fang; Zhentao Yu; Weimin Mao; Jiaqing Xiang; Yongtao Han; Zhijian Chen; Haihua Yang; Jiaming Wang; Qingsong Pang; Xiao Zheng; Huanjun Yang; Tao Li; Florian Lordick; Xavier Benoit D'Journo; Robert J Cerfolio; Robert J Korst; Nuria M Novoa; Scott J Swanson; Alessandro Brunelli; Mahmoud Ismail; Hiran C Fernando; Xu Zhang; Qun Li; Geng Wang; Baofu Chen; Teng Mao; Min Kong; Xufeng Guo; Ting Lin; Mengzhong Liu; Jianhua Fu
Journal:  J Clin Oncol       Date:  2018-08-08       Impact factor: 44.544

View more
  2 in total

1.  Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study.

Authors:  Zelai He; Jia Liu; Yuwei Ma; Hao Jiang; Zhen Cui; Guowen Wang; Yufeng Wu; Jiuzhou Liu; Xixi Cai; Jing Qian; Jingwen Huang; Huijun Zhang; Hongwei Li
Journal:  Cancer Manag Res       Date:  2021-08-04       Impact factor: 3.989

Review 2.  Methodological quality of machine learning-based quantitative imaging analysis studies in esophageal cancer: a systematic review of clinical outcome prediction after concurrent chemoradiotherapy.

Authors:  Zhenwei Shi; Zhen Zhang; Zaiyi Liu; Lujun Zhao; Zhaoxiang Ye; Andre Dekker; Leonard Wee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-23       Impact factor: 10.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.